The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Investigating the combination of tolinapant & decitabine in a pre-clinical model for T-cell lymphoma
Enrica Marchi, MD, PhD, University of Virginia, Charlottesville, VA, discusses a pre-clinical model which investigated the combination of tolinapant and decitabine in T-cell lymphoma. Dr Marchi highlights the early results from this model and explains the synergistic action of tolinapant and decitabine and its potential application in the treatment of T-cell lymphoma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding: Astex Pharmaceuticals, Merck, Celgene/BMS, NomoCan, Kymera Therapeutics
Scientific advisory: Myeloid Therapeutics, Kyowo Kirin, Daiichi Sankyo
